X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216901
https://www.reuters.com/legal/litigation/abbvie-agrees-pay-544-mln-antitrust-case-over-alzheimers-drug-2022-11-14/?rpc=401&
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213985
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204389
https://www.fiercepharma.com/pharma/abbvie-subsidiary-forest-faces-more-litigation-over-alzheimer-s-drug-as-judge-rejects
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210587
https://www.prnewswire.com/news-releases/neurotrope-announces-first-patient-dosed-in-long-term-clinical-trial-of-bryostatin-in-alzheimers-disease-301146563.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210319
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-20-2020-1590042625.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212947
https://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-fda-approval-of-memantine-hydrochloride-extended-release-capsules-301014097.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-26-2020-1582696769.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-19-2020-1582176609.pdf
https://www.accesswire.com/576265/EuMentis-Therapeutics-Inc-Announces-Company-Launch-and-Focus-on-Developing-Novel-Therapeutics-to-Treat-High-Value-Neurodevelopmental-and-Neurodegenerative-Diseases
https://www.reuters.com/article/us-china-drug-alzheimer/china-gives-conditional-ok-to-its-first-self-developed-alzheimers-drug-idUSKBN1XC0JC?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma/allergan-pays-750m-to-settle-alzheimer-s-drug-namenda-forced-switching-suit
https://endpts.com/allergan-ties-up-namenda-loose-ends-with-750m-settlement/
https://www.pharmacompass.com/pdf/news/union-quimico-farmaceutica-fails-edqm-inspection-1572404101.pdf
https://www.politico.com/newsletters/prescription-pulse/2019/08/20/false-claims-suits-pose-new-patent-challenge-pathway-471169
https://endpts.com/what-does-the-past-generation-of-failure-in-alzheimers-rd-look-like-in-one-slide/
https://www.fool.com/investing/2018/08/17/if-i-had-to-buy-1-stock-in-august-it-would-be-this.aspx
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090244
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209955
https://www.fiercepharma.com/pharma/allergan-teva-and-others-raise-prices-more-than-30-drugs-analyst
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-namzaric-memantine-hydrochloride-extended-release-and-donepezil-hydrochloride-1503543880.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208719
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205784
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-shasun-gets-usfda-nod-for-dementia-drug/articleshow/58822441.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202350
https://www.drugtargetreview.com/article/21644/ketamine-depression/
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208328
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205784
http://www.fiercepharma.com/pharma/allergan-offers-conservative-2017-revenue-forecast-mid-single-digit-growth
http://www.biospace.com/News/as-promised-allergan-unveils-single-digit-price/443124/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.reuters.com/article/us-allergan-usa-forestlabs-idUSKBN1442BK
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206135
http://www.fiercepharma.com/marketing/new-indication-for-allergan-s-namrazic-led-to-new-creative-for-common-bonds-campaign
http://www.fiercepharma.com/pharma/as-allergan-shares-languish-icahn-unloads-most-his-700m-stake
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207236
https://www.bloomberg.com/gadfly/articles/2016-11-04/allergan-stock-buyback-try-m-a-instead?
http://www.fiercepharma.com/pharma/growth-pharma-allergan-misses-sales-eps-marks-one-time-blip-or-new-trend
https://www.pharmacompass.com/pdf/news/amneals-generic-memantine-hcl-approved-in-us-1476883578.pdf
https://www.pharmacompass.com/pdf/news/approved-new-list-of-candidate-drugs-to-bioisencao-1475582007.pdf
https://www.pharmacompass.com/pdf/news/mylan-pharms-inc-memantine-hydrochloride-approved-in-us-1475235569.pdf
https://www.pharmacompass.com/pdf/news/amneal-pharms-memantine-hydrochloride-approved-in-us-1475235619.pdf
http://www.prnewswire.com/news-releases/allergan-and-adamas-announce-us-availability-of-new-dosage-strengths-for-namzaric-memantine-and-donepezil-hydrochlorides-extended-release-for-the-treatment-of-moderate-to-severe-alzheimers-disease-300332399.html
http://www.prnewswire.com/news-releases/allergan-and-adamas-announce-new-expanded-indication-for-namzaric-memantine-and-donepezil-hydrochlorides-extended-release-for-the-treatment-of-moderate-to-severe-alzheimers-disease-300300474.html
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ajanta-pharma-launches-anti-dementia-drug-in-us/articleshow/52742080.cms
Market Place
Share 
